ALBANY, N.Y., April 29, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Howard W. Donnelly, 52, has been named Chairman of the Board of Directors, effective immediately.
Mr. Donnelly joined the AngioDynamics Board of Directors in March 2004 and is the President of Concert Medical LLC, a manufacturer of interventional medical devices. In addition, Mr. Donnelly is President and Chief Executive Officer of HydroCision Inc., a medical device manufacturer focused on the spine market. From 1999 to 2002, he was President of Level 1 Inc., a medical device manufacturer and a subsidiary of Smiths Group. From 1990-99, Mr. Donnelly was employed at Pfizer Inc., with his last position being Vice President, Business Planning and Development, for Pfizer's Medical Technology Group from 1997-99.
"I am delighted the other Board members have entrusted me to become AngioDynamics' next Chairman," said Howard Donnelly, Chairman of the Board of Directors. "We have made significant progress commercializing innovative and disruptive products, such as the AngioVac Cannula and Circuit, our BioFlo platform and the Acculis microwave system, driving four quarters of improved sales results and positioning us for continued success."
"Howard's medical device expertise and leadership since joining the Board in 2004 are invaluable, and I look forward to continue working with him and the rest of the Board to ensure we execute our business plan," added Joseph DeVivo, AngioDynamics' President and Chief Executive Officer.
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
AngioDynamics, the AngioDynamics logo, Acculis, AngioVac and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
CONTACT: Company Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Michael Polyviou/Robert Jones (212) 850-6020; (646) 201-5447 email@example.com; firstname.lastname@example.org Media Contact: EVC Group, Inc. Dave Schemelia (646) 201-5431 email@example.comSource:AngioDynamics